New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2013
05:55 EDTADUS, ADUS, ATRS, ATRS, BGMD, BGMD, DSCO, DSCO, EXPR, EXPR, GSOL, GSOL, KOPN, KOPN, PERI, PERI, SNSS, SNSSCompanies reporting Before the Market Open on Wednesday, March 13
Notable companies reporting before the opening bell on Wednesday include Addus Homecare (ADUS), Antares Pharma (ATRS), BG Medicine (BGMD), Discovery Laboratories (DSCO), Express (EXPR), Global Sources (GSOL), Kopin (KOPN), Perion Network (PERI), and Sunesis Pharmaceuticals (SNSS).
Check below for free stories on ADUS;ATRS;BGMD;DSCO;EXPR;GSOL;KOPN;PERI;SNSS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
07:06 EDTATRSAntares Pharma says ARD publishes results from OTREXUP study
Antares Pharma announced that the Annals of the Rheumatic Diseases has published results from an open-label, head-to-head randomized, crossover study comparing the relative bioavailability, safety and tolerability of OTREXUP to oral methotrexate in adult patients with rheumatoid arthritis. In this multicenter, three-way crossover study, patients greater than or equal to 18 years old with adult RA undergoing treatment with MTX for three months or more were assigned to receive one of four dose levels of OTREXUP, 10 mg, 15 mg, 20 mg, and 25 mg weekly in a random sequence of three treatments: oral, subcutaneous into the abdomen and subcutaneous into the thigh. For 24 hours after the administration of each treatment, blood samples were collected to measure drug levels and injection sites were assessed. Forty-seven patients completed the study and the results showed that the systemic availability of methotrexate following oral dosing plateaus at 15 mg and greater. Following administration of OTREXUP, the systemic availability increased proportionally at every dose, which extended the range of exposure compared to patients receiving oral therapy. No unexpected adverse events were noted for either formulation in this short term study and higher systemic MTX exposure was not associated with increases in adverse events.
April 16, 2014
07:03 EDTATRSAntares Pharma announces additional patent coverage for OTREXUP
Antares Pharma announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued versions of U.S. Patents 7,744,582, and 7,776,015. These patents add protection to OTREXUP as well as Antares’ pipeline products. Antares is taking steps to supplement the current Orange Book listings related to OTREXUP.
April 10, 2014
11:31 EDTEXPROptions with increasing implied volatility: EXPR NEE
April 8, 2014
13:30 EDTSNSSSunesis vosaroxin shown to be effective, says Wedbush
Wedbush believes that initial data from a Phase Ib/II study indicates that Sunesis' vosaroxin and decitabine are more effective in treating acute myeloid leukemia and myelodysplastic syndrome than decitabine alone. The firm notes that vosaroxin combined with decitabine appeared to be safe. It reiterates a $10 price target and Outperform rating on Sunesis.
13:00 EDTSNSSSunesis price target raised to $15 from $12 at Roth Capital
Roth Capital raised Buy rated Sunesis' price target to $15 from $12 based on positive Phase I/II combination data with vosaroxin in older front line AML patients announced at AACR.
08:11 EDTSNSSSunesis announces presentation of positive results from Vosaroxin trial
Subscribe for More Information
April 7, 2014
07:27 EDTSNSSAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use